Prometheus Bio Inc.

Located in Hangzhou, China, Prometheus was founded in year 2005. Prometheus is committed to a true partnership with customers by providing fast, high quality and accurate diagnostic products and services. With decades of committed service to the rapid test, Prometheus is focusing on technology, innovation and quality control and developed a broad ranges of product lines including : Drug Test Series; Women’s Health Series; Cardiac Markers Series; Infectious Deseases Series and Tumor Markers Series. Prometheus considered R&D strength as it’s core basis of company development. The core R&D team of Prometheus is located in the heart of silicon valley and lead by senior R&D team which has more than 10 years’ experience in IVD market. By fully understanding of the IVD market, other than the basic product lines, Prometheus has been developing novel products which is able to meet the needs from current market. Now, Prometheus have two brand new platforms: DOA Cup Reader Platform and Up-Converting Fluorescence Quantitative Platform which has been distributing into the market across the world. Guided by our precise technology, we are continuously exchanging knowledge with our customers, partners, and clinicians to address the critical issues of improving care and lowering cost. With over decades of distribution experiences, Prometheus’ major market was in US but now has been built up a solid relationship with worldwide customers from North&South America, Europe, Middle East, South East Asia and Africa. Prometheus’ plant was granted ISO 9001:2008&ISO 13485:2003 certification. In November 2012, Prometheus’ production facility was inspected by US FDA and no 483 form was issued. High standards and compliance, to which Prometheus faithfully adheres, allow our customers to have the utmost confidence in the validity of their project.